Literature DB >> 33268514

The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism.

Alexander T Baker1, James A Davies1, Emily A Bates1, Elise Moses1, Rosie M Mundy1, Gareth Marlow1, David K Cole2, Carly M Bliss1,2, Pierre J Rizkallah2, Alan L Parker3.   

Abstract

The human adenovirus (HAdV) phylogenetic tree is diverse, divided across seven species and comprising over 100 individual types. Species D HAdV are rarely isolated with low rates of preexisting immunity, making them appealing for therapeutic applications. Several species D vectors have been developed as vaccines against infectious diseases, where they induce robust immunity in preclinical models and early phase clinical trials. However, many aspects of the basic virology of species D HAdV, including their basic receptor usage and means of cell entry, remain understudied. Here, we investigated HAdV-D49, which previously has been studied for vaccine and vascular gene transfer applications. We generated a pseudotyped HAdV-C5 presenting the HAdV-D49 fiber knob protein (HAdV-C5/D49K). This pseudotyped vector was efficient at infecting cells devoid of all known HAdV receptors, indicating HAdV-D49 uses an unidentified cellular receptor. Conversely, a pseudotyped vector presenting the fiber knob protein of the closely related HAdV-D30 (HAdV-C5/D30K), differing in four amino acids from HAdV-D49, failed to demonstrate the same tropism. These four amino acid changes resulted in a change in isoelectric point of the knob protein, with HAdV-D49K possessing a basic apical region compared to a more acidic region in HAdV-D30K. Structurally and biologically we demonstrate that HAdV-D49 knob protein is unable to engage CD46, while potential interaction with coxsackievirus and adenovirus receptor (CAR) is extremely limited by extension of the DG loop. HAdV-C5/49K efficiently transduced cancer cell lines of pancreatic, breast, lung, esophageal, and ovarian origin, indicating it may have potential for oncolytic virotherapy applications, especially for difficult to transduce tumor types.IMPORTANCE Adenoviruses are powerful tools experimentally and clinically. To maximize efficacy, the development of serotypes with low preexisting levels of immunity in the population is desirable. Consequently, attention has focused on those derived from species D, which have proven robust vaccine platforms. This widespread usage is despite limited knowledge in their basic biology and cellular tropism. We investigated the tropism of HAdV-D49, demonstrating that it uses a novel cell entry mechanism that bypasses all known HAdV receptors. We demonstrate, biologically, that a pseudotyped HAdV-C5/D49K vector efficiently transduces a wide range of cell lines, including those presenting no known adenovirus receptor. Structural investigation suggests that this broad tropism is the result of a highly basic electrostatic surface potential, since a homologous pseudotyped vector with a more acidic surface potential, HAdV-C5/D30K, does not display a similar pantropism. Therefore, HAdV-C5/D49K may form a powerful vector for therapeutic applications capable of infecting difficult to transduce cells.
Copyright © 2021 Baker et al.

Entities:  

Keywords:  adenoviruses; anticancer therapy; oncolytic viruses; surface receptor

Year:  2021        PMID: 33268514      PMCID: PMC7851562          DOI: 10.1128/JVI.01849-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites.

Authors:  Wim P Burmeister; Delphine Guilligay; Stephen Cusack; Göran Wadell; Niklas Arnberg
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 2.  Adenoviruses: update on structure and function.

Authors:  W C Russell
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

3.  Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Authors:  Hanni Uusi-Kerttula; James A Davies; Jill M Thompson; Phonphimon Wongthida; Laura Evgin; Kevin G Shim; Angela Bradshaw; Alexander T Baker; Pierre J Rizkallah; Rachel Jones; Louise Hanna; Emma Hudson; Richard G Vile; John D Chester; Alan L Parker
Journal:  Clin Cancer Res       Date:  2018-05-24       Impact factor: 12.531

4.  In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor.

Authors:  Theodore Smith; Neeraja Idamakanti; Helen Kylefjord; Michele Rollence; Laura King; Michele Kaloss; Michael Kaleko; Susan C Stevenson
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

5.  The EMBL-EBI bioinformatics web and programmatic tools framework.

Authors:  Weizhong Li; Andrew Cowley; Mahmut Uludag; Tamer Gur; Hamish McWilliam; Silvano Squizzato; Young Mi Park; Nicola Buso; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2015-04-06       Impact factor: 16.971

6.  Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.

Authors:  Alexander T Baker; Alexander Greenshields-Watson; Lynda Coughlan; James A Davies; Hanni Uusi-Kerttula; David K Cole; Pierre J Rizkallah; Alan L Parker
Journal:  Nat Commun       Date:  2019-02-14       Impact factor: 14.919

7.  Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor.

Authors:  Alexander T Baker; Rosie M Mundy; James A Davies; Pierre J Rizkallah; Alan L Parker
Journal:  Sci Adv       Date:  2019-09-04       Impact factor: 14.136

8.  Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood.

Authors:  Y Di; L Seymour; K Fisher
Journal:  Gene Ther       Date:  2014-02-20       Impact factor: 5.250

9.  Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector.

Authors:  Rachel S Dakin; Alan L Parker; Christian Delles; Stuart A Nicklin; Andrew H Baker
Journal:  Hum Gene Ther       Date:  2015-04-02       Impact factor: 5.695

10.  Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.

Authors:  Angelica Loskog; Aglaia Maleka; Sara Mangsbo; Emma Svensson; Christina Lundberg; Anders Nilsson; Johan Krause; Margrét Agnarsdóttir; Anders Sundin; Håkan Ahlström; Thomas H Tötterman; Gustav Ullenhag
Journal:  Br J Cancer       Date:  2016-03-31       Impact factor: 7.640

View more
  2 in total

1.  In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications.

Authors:  Emily A Bates; John R Counsell; Sophie Alizert; Alexander T Baker; Natalie Suff; Ashley Boyle; Angela C Bradshaw; Simon N Waddington; Stuart A Nicklin; Andrew H Baker; Alan L Parker
Journal:  Viruses       Date:  2021-07-28       Impact factor: 5.048

Review 2.  Adenovirus Structure: What Is New?

Authors:  José Gallardo; Marta Pérez-Illana; Natalia Martín-González; Carmen San Martín
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.